Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 10 | 2023 | 2381 | 0.810 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2018 | 329 | 0.520 |
Why?
|
| Atherosclerosis | 4 | 2022 | 950 | 0.430 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2023 | 407 | 0.410 |
Why?
|
| Cardiovascular Diseases | 5 | 2024 | 2287 | 0.410 |
Why?
|
| Echocardiography | 4 | 2023 | 1238 | 0.320 |
Why?
|
| Cardiology | 2 | 2024 | 552 | 0.300 |
Why?
|
| Ventricular Remodeling | 1 | 2008 | 188 | 0.290 |
Why?
|
| Hypertension | 3 | 2024 | 1621 | 0.280 |
Why?
|
| Aortic Stenosis, Subvalvular | 1 | 2005 | 7 | 0.260 |
Why?
|
| Heart Diseases | 2 | 2024 | 736 | 0.250 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2005 | 66 | 0.250 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2005 | 291 | 0.230 |
Why?
|
| Cardiologists | 1 | 2023 | 32 | 0.220 |
Why?
|
| Patient Readmission | 2 | 2018 | 585 | 0.220 |
Why?
|
| Income | 1 | 2024 | 232 | 0.210 |
Why?
|
| Carotid Artery Diseases | 2 | 2015 | 177 | 0.210 |
Why?
|
| Vascular Stiffness | 2 | 2015 | 80 | 0.210 |
Why?
|
| Cardiovascular System | 1 | 2024 | 147 | 0.210 |
Why?
|
| Aortic Valve | 1 | 2005 | 486 | 0.190 |
Why?
|
| Antihypertensive Agents | 1 | 2024 | 442 | 0.190 |
Why?
|
| Warfarin | 1 | 2022 | 152 | 0.190 |
Why?
|
| NF-kappa B | 3 | 2003 | 1569 | 0.180 |
Why?
|
| General Practitioners | 1 | 2019 | 18 | 0.170 |
Why?
|
| Myocytes, Cardiac | 1 | 2003 | 710 | 0.160 |
Why?
|
| Trypanosoma cruzi | 1 | 2021 | 233 | 0.150 |
Why?
|
| Chagas Disease | 1 | 2021 | 288 | 0.150 |
Why?
|
| United States | 9 | 2024 | 16033 | 0.140 |
Why?
|
| Cocaine | 1 | 2018 | 244 | 0.140 |
Why?
|
| Atrial Fibrillation | 1 | 2024 | 747 | 0.130 |
Why?
|
| Thrombosis | 1 | 2022 | 754 | 0.130 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 555 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2018 | 322 | 0.130 |
Why?
|
| Pericardial Window Techniques | 1 | 2015 | 6 | 0.130 |
Why?
|
| Physicians | 1 | 2023 | 868 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 658 | 0.120 |
Why?
|
| Postprandial Period | 1 | 2015 | 86 | 0.120 |
Why?
|
| Ventricular Dysfunction | 1 | 2015 | 33 | 0.120 |
Why?
|
| Acute Coronary Syndrome | 1 | 2018 | 252 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 3854 | 0.120 |
Why?
|
| Myocardial Infarction | 1 | 2003 | 1300 | 0.120 |
Why?
|
| Cardiac Tamponade | 1 | 2015 | 51 | 0.120 |
Why?
|
| Humans | 31 | 2024 | 272039 | 0.120 |
Why?
|
| Carotid Arteries | 1 | 2015 | 249 | 0.110 |
Why?
|
| Pericardial Effusion | 1 | 2015 | 125 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 767 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 943 | 0.110 |
Why?
|
| Dietary Fats | 1 | 2015 | 350 | 0.110 |
Why?
|
| Hyperlipidemias | 1 | 2015 | 235 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 748 | 0.110 |
Why?
|
| Peptide Fragments | 1 | 2018 | 1322 | 0.110 |
Why?
|
| Carotid Artery, Common | 1 | 2011 | 94 | 0.090 |
Why?
|
| American Heart Association | 2 | 2024 | 329 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2019 | 1326 | 0.090 |
Why?
|
| Ventricular Function, Left | 3 | 2023 | 570 | 0.090 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 186 | 0.090 |
Why?
|
| Stroke Volume | 2 | 2023 | 552 | 0.090 |
Why?
|
| Prevalence | 3 | 2024 | 3417 | 0.090 |
Why?
|
| Adult | 12 | 2024 | 81993 | 0.080 |
Why?
|
| Apoptosis | 1 | 2003 | 7842 | 0.080 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2022 | 349 | 0.080 |
Why?
|
| Myocardial Ischemia | 2 | 2021 | 431 | 0.080 |
Why?
|
| Vena Cava, Superior | 1 | 2009 | 78 | 0.080 |
Why?
|
| Receptors, Cell Surface | 2 | 2002 | 911 | 0.080 |
Why?
|
| Neurotransmitter Agents | 1 | 2008 | 171 | 0.070 |
Why?
|
| Membrane Glycoproteins | 2 | 2002 | 1106 | 0.070 |
Why?
|
| Male | 14 | 2024 | 129081 | 0.070 |
Why?
|
| Female | 15 | 2024 | 149291 | 0.070 |
Why?
|
| Drosophila Proteins | 2 | 2002 | 908 | 0.060 |
Why?
|
| Middle Aged | 9 | 2024 | 90457 | 0.060 |
Why?
|
| Risk Factors | 4 | 2024 | 18024 | 0.060 |
Why?
|
| Chest Pain | 1 | 2005 | 172 | 0.060 |
Why?
|
| Renin-Angiotensin System | 1 | 2024 | 110 | 0.060 |
Why?
|
| Cytoprotection | 1 | 2003 | 66 | 0.060 |
Why?
|
| Hospitalization | 2 | 2024 | 2183 | 0.060 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2003 | 138 | 0.060 |
Why?
|
| Ligation | 1 | 2003 | 208 | 0.060 |
Why?
|
| Heart Ventricles | 3 | 2022 | 847 | 0.050 |
Why?
|
| I-kappa B Proteins | 1 | 2003 | 177 | 0.050 |
Why?
|
| Lipopolysaccharides | 2 | 2002 | 593 | 0.050 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2002 | 90 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1433 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 1070 | 0.050 |
Why?
|
| Vitamin K | 1 | 2022 | 54 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2022 | 61 | 0.050 |
Why?
|
| Dyspnea | 1 | 2005 | 420 | 0.050 |
Why?
|
| Mortality | 1 | 2024 | 351 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2024 | 360 | 0.050 |
Why?
|
| Growth Substances | 1 | 2002 | 329 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2024 | 319 | 0.050 |
Why?
|
| Shock, Septic | 1 | 2002 | 187 | 0.050 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2002 | 194 | 0.050 |
Why?
|
| Insect Vectors | 1 | 2021 | 113 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2003 | 408 | 0.050 |
Why?
|
| Echocardiography, Stress | 1 | 2020 | 18 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2024 | 362 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 16252 | 0.040 |
Why?
|
| Heart-Assist Devices | 1 | 2008 | 1050 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2021 | 321 | 0.040 |
Why?
|
| Aged | 5 | 2024 | 73500 | 0.040 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2020 | 88 | 0.040 |
Why?
|
| Coronary Vessels | 1 | 2003 | 642 | 0.040 |
Why?
|
| Age of Onset | 1 | 2021 | 855 | 0.040 |
Why?
|
| Bisoprolol | 1 | 2018 | 12 | 0.040 |
Why?
|
| Cholesterol | 1 | 2022 | 681 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 673 | 0.040 |
Why?
|
| Texas | 2 | 2021 | 6433 | 0.040 |
Why?
|
| Inpatients | 1 | 2024 | 695 | 0.040 |
Why?
|
| Atenolol | 1 | 2018 | 46 | 0.040 |
Why?
|
| Propanolamines | 1 | 2018 | 48 | 0.040 |
Why?
|
| Metoprolol | 1 | 2018 | 27 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2024 | 1598 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 2424 | 0.040 |
Why?
|
| Cerebellum | 1 | 2002 | 477 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2020 | 315 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2024 | 1317 | 0.040 |
Why?
|
| Propranolol | 1 | 2018 | 160 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2002 | 690 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 1850 | 0.040 |
Why?
|
| Telephone | 1 | 2018 | 160 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2018 | 106 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 1286 | 0.040 |
Why?
|
| Disease Progression | 1 | 2008 | 6909 | 0.040 |
Why?
|
| Ischemia | 1 | 2020 | 408 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 790 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2024 | 2289 | 0.030 |
Why?
|
| Sex Factors | 1 | 2021 | 2201 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2002 | 1310 | 0.030 |
Why?
|
| Heart | 1 | 2002 | 1211 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 4372 | 0.030 |
Why?
|
| Pulse Wave Analysis | 1 | 2015 | 49 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 878 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2024 | 39828 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 178 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 847 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2015 | 1941 | 0.030 |
Why?
|
| Animals | 6 | 2021 | 62826 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2013 | 85 | 0.030 |
Why?
|
| Prognosis | 2 | 2020 | 22543 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2003 | 1606 | 0.030 |
Why?
|
| Time Factors | 2 | 2018 | 13135 | 0.030 |
Why?
|
| Cyclic GMP | 2 | 2002 | 124 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 1111 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 6208 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2002 | 267 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 2 | 2002 | 329 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 4512 | 0.020 |
Why?
|
| Toll-Like Receptors | 2 | 2002 | 170 | 0.020 |
Why?
|
| Blood Pressure Determination | 1 | 2011 | 115 | 0.020 |
Why?
|
| Interleukin-1 | 2 | 2002 | 477 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 1243 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2015 | 33913 | 0.020 |
Why?
|
| Young Adult | 2 | 2020 | 22173 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 2867 | 0.020 |
Why?
|
| Hemodynamics | 2 | 2002 | 967 | 0.020 |
Why?
|
| Mice | 3 | 2003 | 36058 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2020 | 6882 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2009 | 282 | 0.020 |
Why?
|
| Myocardium | 2 | 2002 | 1249 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 5941 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2002 | 2457 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 5519 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 5194 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2003 | 208 | 0.010 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2002 | 56 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2002 | 188 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 2002 | 407 | 0.010 |
Why?
|
| Dimerization | 1 | 2002 | 318 | 0.010 |
Why?
|
| Transcription Factor RelA | 1 | 2002 | 186 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 2002 | 186 | 0.010 |
Why?
|
| Molecular Chaperones | 1 | 2002 | 268 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2002 | 209 | 0.010 |
Why?
|
| Biological Transport | 1 | 2002 | 645 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 31071 | 0.010 |
Why?
|
| Algorithms | 1 | 2011 | 3922 | 0.010 |
Why?
|
| Antirheumatic Agents | 1 | 2003 | 229 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2002 | 719 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 2003 | 669 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2002 | 1718 | 0.010 |
Why?
|
| Cardiac Catheterization | 1 | 2002 | 692 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2002 | 1197 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2002 | 1740 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 4635 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 6783 | 0.010 |
Why?
|
| Cytokines | 1 | 2003 | 2830 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 3417 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 7792 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2002 | 5841 | 0.010 |
Why?
|
| Inflammation | 1 | 2002 | 2533 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 6489 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 7239 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2002 | 12228 | 0.000 |
Why?
|